A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Male or female, 18 - 60 years old (inclusive).
• History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
• Nausea or vomiting.
• Presence of rash, aches or pains including headache, muscle or joint pain.
• Onset of fever ≤ 48 hours prior to treatment start.
• Positive test on dengue fever.
Locations
Other Locations
Brazil
Novartis Investigative Site
RECRUITING
Brasília
Novartis Investigative Site
RECRUITING
Manaus
Novartis Investigative Site
RECRUITING
Rio De Janeiro
Novartis Investigative Site
RECRUITING
São José Do Rio Preto
Novartis Investigative Site
RECRUITING
Sorocaba
Colombia
Novartis Investigative Site
RECRUITING
Santiago De Cali
India
Novartis Investigative Site
RECRUITING
Belagavi
Novartis Investigative Site
RECRUITING
Chennai
Novartis Investigative Site
RECRUITING
Jaipur
Novartis Investigative Site
WITHDRAWN
Mumbai
Novartis Investigative Site
RECRUITING
Pune
Malaysia
Novartis Investigative Site
RECRUITING
Ipoh
Novartis Investigative Site
RECRUITING
Kuantan
Novartis Investigative Site
RECRUITING
Miri
Novartis Investigative Site
RECRUITING
Seberang Jaya
Singapore
Novartis Investigative Site
RECRUITING
Singapore
Novartis Investigative Site
RECRUITING
Singapore
Viet Nam
Novartis Investigative Site
RECRUITING
Haiphong
Novartis Investigative Site
RECRUITING
Hanoi
Novartis Investigative Site
RECRUITING
Ho Chi Minh City
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2024-02-20
Estimated Completion Date: 2026-09-07
Participants
Target number of participants: 108
Treatments
Experimental: EYU688
EYU688 administered by oral route
Placebo_comparator: Placebo
Matching placebo
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals